AU2014348454A1 - Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses - Google Patents
Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses Download PDFInfo
- Publication number
- AU2014348454A1 AU2014348454A1 AU2014348454A AU2014348454A AU2014348454A1 AU 2014348454 A1 AU2014348454 A1 AU 2014348454A1 AU 2014348454 A AU2014348454 A AU 2014348454A AU 2014348454 A AU2014348454 A AU 2014348454A AU 2014348454 A1 AU2014348454 A1 AU 2014348454A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- placental perfusate
- composition
- subject
- human placental
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003169 placental effect Effects 0.000 title claims abstract description 672
- 239000000203 mixture Substances 0.000 title claims abstract description 137
- 210000004027 cell Anatomy 0.000 claims abstract description 1100
- 238000000034 method Methods 0.000 claims abstract description 99
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 29
- 206010068051 Chimerism Diseases 0.000 claims abstract description 27
- 208000001738 Nervous System Trauma Diseases 0.000 claims abstract description 19
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 19
- 208000009329 Graft vs Host Disease Diseases 0.000 claims abstract description 18
- 208000024908 graft versus host disease Diseases 0.000 claims abstract description 18
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 claims abstract description 16
- 208000019838 Blood disease Diseases 0.000 claims abstract description 11
- 208000014951 hematologic disease Diseases 0.000 claims abstract description 11
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 11
- 208000001076 sarcopenia Diseases 0.000 claims abstract description 11
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims abstract description 10
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims abstract description 10
- 208000009973 brain hypoxia - ischemia Diseases 0.000 claims abstract description 10
- 208000033300 perinatal asphyxia Diseases 0.000 claims abstract description 10
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims description 302
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims description 302
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 47
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 47
- 210000002826 placenta Anatomy 0.000 claims description 45
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 36
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 35
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 33
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 33
- 102000008730 Nestin Human genes 0.000 claims description 32
- 108010088225 Nestin Proteins 0.000 claims description 32
- 210000005055 nestin Anatomy 0.000 claims description 32
- 208000012902 Nervous system disease Diseases 0.000 claims description 30
- 230000010412 perfusion Effects 0.000 claims description 22
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 21
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 21
- 208000028412 nervous system injury Diseases 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 8
- 201000005787 hematologic cancer Diseases 0.000 claims description 7
- 230000036210 malignancy Effects 0.000 claims description 7
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 6
- 210000005087 mononuclear cell Anatomy 0.000 abstract description 13
- 208000024891 symptom Diseases 0.000 abstract description 12
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 6
- 210000004700 fetal blood Anatomy 0.000 description 149
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 22
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 21
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 21
- 210000003954 umbilical cord Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 18
- 210000000130 stem cell Anatomy 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 230000037396 body weight Effects 0.000 description 14
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 210000005259 peripheral blood Anatomy 0.000 description 13
- 239000011886 peripheral blood Substances 0.000 description 13
- 238000003556 assay Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 11
- 230000036266 weeks of gestation Effects 0.000 description 10
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 9
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 9
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 8
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 8
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 description 8
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 210000003289 regulatory T cell Anatomy 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 6
- 208000035010 Term birth Diseases 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 108091092878 Microsatellite Proteins 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 208000005107 Premature Birth Diseases 0.000 description 4
- 239000002458 cell surface marker Substances 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 210000005166 vasculature Anatomy 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 3
- 235000019270 ammonium chloride Nutrition 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004993 mammalian placenta Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 230000002028 premature Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 2
- -1 CD 117 Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000001401 hemangioblastic effect Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000001126 phototherapy Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 210000004991 placental stem cell Anatomy 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102100033051 40S ribosomal protein S19 Human genes 0.000 description 1
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 208000033932 Blackfan-Diamond anemia Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 description 1
- 201000004449 Diamond-Blackfan anemia Diseases 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 206010062018 Inborn error of metabolism Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 208000022806 beta-thalassemia major Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009640 blood culture Methods 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002338 cryopreservative effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 201000008049 fucosidosis Diseases 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 229940027278 hetastarch Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000998 lymphohematopoietic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 230000001400 myeloablative effect Effects 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 210000004663 osteoprogenitor cell Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 1
- KYITYFHKDODNCQ-UHFFFAOYSA-M sodium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [Na+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 KYITYFHKDODNCQ-UHFFFAOYSA-M 0.000 description 1
- 108010048090 soybean lectin Proteins 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 229960002647 warfarin sodium Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2020202182A AU2020202182A1 (en) | 2013-11-15 | 2020-03-27 | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
| AU2022215291A AU2022215291A1 (en) | 2013-11-15 | 2022-08-12 | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361905076P | 2013-11-15 | 2013-11-15 | |
| US201361905077P | 2013-11-15 | 2013-11-15 | |
| US61/905,076 | 2013-11-15 | ||
| US61/905,077 | 2013-11-15 | ||
| PCT/US2014/065665 WO2015073800A2 (en) | 2013-11-15 | 2014-11-14 | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020202182A Division AU2020202182A1 (en) | 2013-11-15 | 2020-03-27 | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2014348454A1 true AU2014348454A1 (en) | 2016-06-02 |
Family
ID=53058264
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014348454A Abandoned AU2014348454A1 (en) | 2013-11-15 | 2014-11-14 | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
| AU2020202182A Abandoned AU2020202182A1 (en) | 2013-11-15 | 2020-03-27 | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
| AU2022215291A Abandoned AU2022215291A1 (en) | 2013-11-15 | 2022-08-12 | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020202182A Abandoned AU2020202182A1 (en) | 2013-11-15 | 2020-03-27 | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
| AU2022215291A Abandoned AU2022215291A1 (en) | 2013-11-15 | 2022-08-12 | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160279171A1 (https=) |
| EP (1) | EP3068432A4 (https=) |
| JP (4) | JP2016537362A (https=) |
| KR (3) | KR20240023709A (https=) |
| CN (2) | CN105916521A (https=) |
| AU (3) | AU2014348454A1 (https=) |
| CA (1) | CA2930573C (https=) |
| MX (2) | MX2016006270A (https=) |
| RU (1) | RU2016123361A (https=) |
| WO (1) | WO2015073800A2 (https=) |
| ZA (1) | ZA201603270B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11707491B2 (en) * | 2016-11-11 | 2023-07-25 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Methods of treating neurodegenerative disorders |
| EP4417210A1 (en) * | 2017-03-15 | 2024-08-21 | Orca Biosystems, Inc. | Compositions and methods for hematopoietic stem cell transplants |
| KR20210111244A (ko) * | 2018-11-30 | 2021-09-10 | 셀룰래리티 인코포레이티드 | 태반-유래 동종이계 car-t 세포 및 이의 용도 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10001172A1 (de) | 2000-01-13 | 2001-07-26 | Max Planck Gesellschaft | Templatieren von Feststoffpartikeln mit Polymermultischichten |
| US20080152629A1 (en) * | 2000-12-06 | 2008-06-26 | James Edinger | Placental stem cell populations |
| DK1349918T3 (da) | 2000-12-06 | 2014-11-10 | Anthrogenesis Corp | Fremgangsmåde til indsamling af stamceller fra moderkagen |
| US7311905B2 (en) * | 2002-02-13 | 2007-12-25 | Anthrogenesis Corporation | Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells |
| EP2316919B1 (en) * | 2001-02-14 | 2015-10-07 | Anthrogenesis Corporation | Post-partum mammalian placenta, its use and placental stem cells therefrom |
| EP3246396B1 (en) * | 2001-02-14 | 2020-01-29 | Celularity, Inc. | Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells |
| US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| WO2005094353A2 (en) * | 2004-03-29 | 2005-10-13 | Cytomatrix, Llc | Methods for production of regulatory t cells and uses thereof |
| DK1957633T3 (en) * | 2005-10-13 | 2014-03-17 | Anthrogenesis Corp | Immunomodulation USING PLACE SPEECH STEM CELLS |
| CN101389754A (zh) | 2005-12-29 | 2009-03-18 | 人类起源公司 | 胎盘干细胞和第二来源干细胞的联合培养 |
| PT2471904T (pt) | 2005-12-29 | 2019-02-25 | Celularity Inc | População de células estaminais placentárias |
| NZ570614A (en) * | 2006-01-23 | 2012-07-27 | Athersys Inc | Multipotent adult progenitor cell treatment of brain injuries and diseases |
| EP2023717B1 (en) * | 2006-05-11 | 2016-04-13 | Anthrogenesis Corporation | Methods for collecting placenta cord blood stem cells |
| ZA200902233B (en) * | 2006-10-23 | 2010-07-28 | Anthrogenesis Corp | Methods and compositions for treatment of bone defects with placental cell populations |
| AU2008216748A1 (en) * | 2007-02-12 | 2008-08-21 | Anthrogenesis Corporation | Hepatocytes and chondrocytes from adherent placental stem cells; and CD34+, CD45- placental stem cell-enriched cell populations |
| EP2164953A4 (en) * | 2007-06-18 | 2010-06-30 | Childrens Hosp & Res Ct Oak | METHOD OF ISOLATING STAIN AND PRECIPITATING CELLS FROM PLAZENTA |
| CA2700613C (en) * | 2007-09-26 | 2022-09-20 | Celgene Cellular Therapeutics | Angiogenic cells from human placental perfusate |
| NZ599825A (en) | 2007-09-28 | 2014-10-31 | Anthrogenesis Corp | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
| NZ592839A (en) | 2008-11-21 | 2012-10-26 | Anthrogenesis Corp | Treatment of diseases, disorders or conditions of the lung using placental cells |
| WO2010105144A2 (en) * | 2009-03-12 | 2010-09-16 | University Of South Florida | Method of disease-induced and receptor-mediated stem cell neuroprotection |
| US20100323446A1 (en) * | 2009-06-05 | 2010-12-23 | Jill Renee Barnett | Method of collecting placental cells |
| US20120177618A1 (en) * | 2009-07-14 | 2012-07-12 | Massachusetts Institute Of Technology | Hematopoietic stromal progenitor cells and uses thereof |
| US20110280849A1 (en) | 2010-03-26 | 2011-11-17 | Anthrogenesis Corporation | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
| LT2556145T (lt) * | 2010-04-07 | 2016-11-10 | Anthrogenesis Corporation | Angiogenezė naudojant placentos kamienines ląsteles |
| ES2666746T3 (es) * | 2010-07-13 | 2018-05-07 | Anthrogenesis Corporation | Métodos para generar linfocitos citolíticos naturales |
| MX2013006592A (es) * | 2010-12-17 | 2014-02-06 | Anthrogenesis Corp | Tratamiento de lesion de la medula espinal y lesion traumatica de cerebro empleando celulas adherentes obtenidas del amnios. |
| KR20130128438A (ko) * | 2010-12-17 | 2013-11-26 | 안트로제네시스 코포레이션 | 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료 |
| US20120171180A1 (en) | 2010-12-30 | 2012-07-05 | Sascha Abramson | Compositions comprising amnion derived adherent cells and platelet-rich plasma |
| WO2013055476A1 (en) | 2011-09-09 | 2013-04-18 | Anthrogenesis Corporation | Treatment of amyotrophic lateral sclerosis using placental stem cells |
| JP2015526088A (ja) * | 2012-08-13 | 2015-09-10 | アントフロゲネシス コーポレーション | ナチュラルキラー細胞及びその使用 |
| EP2909314B1 (en) | 2012-10-19 | 2020-12-02 | Celularity, Inc. | Treatment of pain using amnion derived adherent cells |
-
2014
- 2014-11-14 CN CN201480073194.6A patent/CN105916521A/zh active Pending
- 2014-11-14 KR KR1020247005001A patent/KR20240023709A/ko not_active Ceased
- 2014-11-14 WO PCT/US2014/065665 patent/WO2015073800A2/en not_active Ceased
- 2014-11-14 CN CN202110968902.4A patent/CN113679740A/zh active Pending
- 2014-11-14 KR KR1020167015654A patent/KR20160098244A/ko not_active Ceased
- 2014-11-14 MX MX2016006270A patent/MX2016006270A/es unknown
- 2014-11-14 AU AU2014348454A patent/AU2014348454A1/en not_active Abandoned
- 2014-11-14 RU RU2016123361A patent/RU2016123361A/ru unknown
- 2014-11-14 CA CA2930573A patent/CA2930573C/en active Active
- 2014-11-14 KR KR1020217030425A patent/KR20210121277A/ko not_active Ceased
- 2014-11-14 JP JP2016530925A patent/JP2016537362A/ja active Pending
- 2014-11-14 EP EP14862931.4A patent/EP3068432A4/en not_active Withdrawn
- 2014-11-14 US US15/036,649 patent/US20160279171A1/en not_active Abandoned
-
2016
- 2016-05-13 MX MX2021003799A patent/MX2021003799A/es unknown
- 2016-05-13 ZA ZA2016/03270A patent/ZA201603270B/en unknown
-
2018
- 2018-11-23 US US16/199,116 patent/US20190117705A1/en not_active Abandoned
-
2019
- 2019-09-06 JP JP2019162780A patent/JP2020019777A/ja not_active Withdrawn
-
2020
- 2020-03-27 AU AU2020202182A patent/AU2020202182A1/en not_active Abandoned
-
2021
- 2021-09-24 JP JP2021155038A patent/JP2022020622A/ja not_active Withdrawn
-
2022
- 2022-08-12 AU AU2022215291A patent/AU2022215291A1/en not_active Abandoned
-
2023
- 2023-10-12 JP JP2023176697A patent/JP2024016037A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160279171A1 (en) | 2016-09-29 |
| KR20240023709A (ko) | 2024-02-22 |
| AU2022215291A9 (en) | 2022-11-24 |
| EP3068432A4 (en) | 2017-04-19 |
| CA2930573A1 (en) | 2015-05-21 |
| JP2016537362A (ja) | 2016-12-01 |
| AU2022215291A1 (en) | 2022-09-01 |
| WO2015073800A2 (en) | 2015-05-21 |
| ZA201603270B (en) | 2022-09-28 |
| CN105916521A (zh) | 2016-08-31 |
| JP2022020622A (ja) | 2022-02-01 |
| CN113679740A (zh) | 2021-11-23 |
| RU2016123361A (ru) | 2017-12-20 |
| JP2024016037A (ja) | 2024-02-06 |
| AU2020202182A1 (en) | 2020-04-16 |
| KR20210121277A (ko) | 2021-10-07 |
| JP2020019777A (ja) | 2020-02-06 |
| WO2015073800A8 (en) | 2015-12-17 |
| MX2016006270A (es) | 2016-09-07 |
| KR20160098244A (ko) | 2016-08-18 |
| US20190117705A1 (en) | 2019-04-25 |
| EP3068432A2 (en) | 2016-09-21 |
| CA2930573C (en) | 2023-12-05 |
| MX2021003799A (es) | 2021-06-04 |
| WO2015073800A3 (en) | 2015-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6853081B2 (ja) | Ｈｌａの適合なしに造血機能を提供するための組成物および方法 | |
| AU2022215291A9 (en) | Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses | |
| JP2020090529A (ja) | 造血機能を提供するための組成物および方法 | |
| US20050118142A1 (en) | Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd | |
| Kelly et al. | Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies | |
| US20240408198A1 (en) | Therapeutic compositions and methods for allogeneic hematopoietic stem cell transplantation | |
| AU2017414804B2 (en) | Selection and use of umbilical cord cell fractions suitable for transplantation | |
| AU2018270407B2 (en) | Selection and use of umbilical cord cell fractions suitable for transplantation | |
| Basford et al. | The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells | |
| Basford et al. | Umbilical cord blood processing using Prepacyte‐CB increases haematopoietic progenitor cell availability over conventional Hetastarch separation | |
| CN119278262A (zh) | 方法 | |
| JP2025146940A (ja) | 拡大した幹細胞生成物を使用して、血液悪性腫瘍を有する患者の処置転帰を改善するための組成物および方法 | |
| Kanold | Maternal microchimerism | |
| Kanold | DEPARTMENT OF CLINICAL SCIENCE, INTERVENTION AND TECHNOLOGY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: CELULARITY, INC. Free format text: FORMER APPLICANT(S): ANTHROGENESIS CORPORATION |
|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |